Athersys Stock News

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ATHX--Peer-reviewed publication provides evidence of MAPC / MultiStem mechanisms of action on the inflammatory response by promoting Treg differentiation.

Athersys' MultiStem lead ischemic stroke indication is struggling with pandemic-induced slowdowns to complete trials in the US and Japan. Athersys' runner-up indication, MultiStem in the treatment of

Athersys, Inc. (ATHX) Management on Q1 2021 Results - Earnings Call Transcript

CLEVELAND--(BUSINESS WIRE)---- $ATHX #earnings--Athersys, Inc. will host its first quarter 2021 financial results call on Thursday, May 6, 2021 at 4:30 PM EDT.

The biotech's partner completed enrollment in a key clinical study.

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys partner in Japan, HEALIOS KK, completes enrollment in the ONE-BRIDGE study evaluating MulitiStem cell therapy for the treatment of ARDS.

Athersys' (ATHX) Management on Q4 Full Year 2020 Results - Earnings Call Transcript

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.

Longeveron Seeks $25 Million IPO For Anti-Aging Efforts

MultiStem partners battle in nasty board fight. Japan Results in Stroke and ARDS 90+% enrolled.

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.

Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

The biotech announced the enrollment of the first patient in a key clinical study.